GLUE Monte Rosa Therapeutics, Inc.: institutional ownership and insider trading
204 funds reported holding $2.32B of Monte Rosa Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $137M, with 27 new positions and 23 funds selling out; over the last 12 months insiders bought $0 and sold $4.11M on the open market.
Famous investors holding GLUE
- Stanley Druckenmiller (Duquesne Family Office): $7.20M, 0.1% of the portfolio
- Ken Griffin (Citadel Advisors): $4.17M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $4.16M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $3.41M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $2.48M, 0.0% of the portfolio
Largest institutional holders of GLUE
- PRICE T ROWE ASSOCIATES INC /MD/ — $214M
- NEA Management Company, LLC — $186M
- BlackRock, Inc. (BLK) — $166M
- TCG Crossover Management, LLC — $112M
- Vestal Point Capital, LP — $111M
- BVF INC/IL — $108M
- BAKER BROS. ADVISORS LP — $105M
- STATE STREET CORP (STT, STT-PG) — $90.3M
- SUVRETTA CAPITAL MANAGEMENT, LLC — $85.9M
- VANGUARD CAPITAL MANAGEMENT LLC — $82.6M
Recent GLUE insider trades
- Oct 5, 2026: Bowen Matthew sold 13 shares ($137)
- Jul 16, 2026: Warmuth Markus sold 9,500 shares ($220K)
- Jul 15, 2026: Champoux Jennifer sold 4,351 shares ($102K)
- Jul 6, 2026: Townson Sharon sold 6,000 shares ($140K)
5%+ owners
- T. Rowe Price Associates, Inc.: 10.5% (Schedule 13G/A, filed Jul 8, 2026)
- Baker Bros. Advisors LP: 10.0% (Schedule 13G/A, filed May 15, 2026)
- Ali Behbahani: 9.7% (Schedule 13D/A, filed Mar 19, 2026)
- Adam Goulburn: 8.1% (Schedule 13G/A, filed Apr 22, 2026)
- New Enterprise Associates 17, L.P.: 7.9% (Schedule 13D/A, filed Jul 6, 2026)
- BVF PARTNERS L P/IL: 6.3% (Schedule 13G/A, filed May 15, 2026)